Cancer pill ‘gave me four years of extra time’

Linda Kelly, 67, has advanced breast cancer that has spread to her bones and chest wall, but says that a new pill gives her additional years of life and time to travel with her husband.

“It allows you to have a normal son of life and forget that it has cancer,” he says about the new Capivasertib medication, which has been recruited for the use of NHS in England and Wales, and is financed in England.

Linda is one of the more than 1,000 women with incurable breast cancer that could be of the medication, which can delay the progression of the disease.

It is another possible treatment option for those with this cancer, but a beneficial organization said that breast cancer medications should be approved more quickly.

Linda is a large gardener that is kept active when rising 60 miles per week and also Pilates.

She says she is “fantastic” results of the new drug, which are tasks twice a day in the form of a tablet.

The side effects for its minimum and allow you to go on vacation to New Zealand with your husband Neil last year and plan a trip to the United States this year.

“You feel that the drug is working and you can be much quieter, it has given me almost four years of extra time,” she says.

She says that the drug has also given her hope.

“It makes you think of your life and what you want to do with your life in the future, but at least you feel good enough to make those plans and safe enough to fulfill those plans.”

But it is likely that not everyone has such positive results in the drug.

In tests, in 708 women, When combined with hormonal therapyThe medicine doubled the time that cancer toks grew, from 3.6 months to 7.3 months, and reduced tumors in 23% of patients.

“It presents a very effective option that can work for a long time, many months, and in some people it can be year,” said Professor Nick Turner, principal researcher and medical oncology professor at the Cancer Research Institute and Royal Marsden.

“The chemotherapy that many women fear due to side effects can delay substantial,” he added.

“Advanced breast cancer is highly treatable and we want more friendly and better treatments.”

The medicine, which has been approved by the National Institute of Excellence in Health and Care (NICE), will be financed through the Cancer Medicines Fund in England, but financing has not yet been confirmed in Wales.

Breast cancer is the most common cancer in the United Kingdom, with one in seven women affected in their lives and 75% survives for 10 years or more after diagnosis.

If cancer returns and spreads to other parts of the body, treatments aim to control it, reduce symptoms and improve the quality of life.

Possible treatments include chemotherapy, radiotherapy and medications that help stop cancer growth, either blocking hormones, increasing the body’s immune system or aimed at what cancer cells grow.

This new Captiveib medication is a directed therapy. It works in a new way, blocking the activity of a protein molecule called AKT that drives cancer growth.

Scientists began working on the development of the medication 20 years ago and they say it is the most effective cancer medication they have seen for advanced cancer. Astrazeneca is the manufacturer or captive.

The medicine is suitable for those with certain genetic mutations that affect up to half people with positive secondary breast cancer of the hormonal receptor, the most common type, which grows in the presence of estrogen.

Professor Peter Johnson, clinical director of Cancer at NHS England, said he offered “an additional option” for some whose cancer has progressed despite previous hormonal therapy, but would not be suitable for everyone.

Claire Rowney, executive director of Charity Breast Cancer Now, said she was “delighted” that the drug would sacrifice some people “the hope of a more precious time to do what matters most to them.”

But she said that patients had “faced unnecessary delays to access it” after the medication was initially rejected by Nice, and breast cancer medications should be approved more quickly for those who need them.

“NHS England must now establish genetic evidence promoted to ensure that those eligible Capivertibs without further delay,” he said, added that Scotland should also consider financing the treatment quickly so that patients are silenced. Than acrross patients. Than acrosts patients. What acrosens patients.

Speaking in the BBC Radio 4 program, Professor Johnson said Nice had to overcome the evidence when addressing new drugs for NHS, and those discussions included how much the medicine will cost.

“We have to ensure that the treatments we provide are a good value for money -price for the NHS and that they are under the threshold of costs that we expect, because obviously, particularly in these difficult times, money is not abundant and we must ensure that the price of the medication and the way they are used really constitutes … good quality relationship

Niza says he has approved 24 of 25 breast cancer treatments that he has evaluated in the last seven years.

Get our flagship bulletin with all the headlines you need to start the day. Register here.